Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study

OBJECTIVES: There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases. This study evaluated placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis factor drug, from CZP-treated pregnant women to their infants. METHODS: CRIB...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariette, Xavier, Förger, Frauke, Abraham, Bincy, Flynn, Ann D, Moltó, Anna, Flipo, René-Marc, van Tubergen, Astrid, Shaughnessy, Laura, Simpson, Jeff, Teil, Marie, Helmer, Eric, Wang, Maggie, Chakravarty, Eliza F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867410/
https://www.ncbi.nlm.nih.gov/pubmed/29030361
http://dx.doi.org/10.1136/annrheumdis-2017-212196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867410/
https://www.ncbi.nlm.nih.gov/pubmed/29030361
http://dx.doi.org/10.1136/annrheumdis-2017-212196

Ejemplares similares